Pharma BD Deal Intelligence

Bristol-Myers Squibb Company / ZymoGenetics, Inc.

2010 · Acquisition/Merger · $885M · Complete

Announcement Sentiment

Positive

BMS agreed to acquire ZymoGenetics for $9.75/share cash, ~$885M aggregate (~$735M net of cash). Strengthened HCV portfolio (PEG-IFN lambda) and oncology pipeline.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Assets Terminated

Assessment window: 15yr post-close.

Key facts

Announced Sep 07, 2010
Closed Oct 12, 2010
Deal value $885M
Deal type Acquisition/Merger
Therapeutic area Hepatitis C; metastatic melanoma
Indications Hepatitis C; metastatic melanoma
Key assets PEG-Interferon lambda; IL-21 (recombinant)
Mechanism Type III interferon; cytokine immunotherapy

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals